Overview

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

Status:
Unknown status

Trial end date:
2018-09-01

Target enrollment:

Participant gender:

Summary

To Determine the the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral β-Amyloid When Compared With Postmortem Histopathology

Phase:

Phase 3

Details

Lead Sponsor:

Navidea Biopharmaceuticals